Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Burkitt Lymphoma 1

Interventions

pembrolizumab 31Carboplatin 24Specimen Handling 19Magnetic Resonance Spectroscopy 17Cyclophosphamide 17Nivolumab 14Dexamethasone 14Bevacizumab 13fludarabine 12atezolizumab 11Temozolomide 11Gemcitabine 11Biopsy 11Paclitaxel 10venetoclax 9Pemetrexed 9Ipilimumab 9Cisplatin 8Rituximab 7Prednisone 7Oxaliplatin 7Lenalidomide 7Fluorouracil 7Docetaxel 7Capecitabine 7olaparib 6Vincristine 6Leucovorin 6patritumab deruxtecan 5lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Spinal Puncture × 30 days × Clear all
NCT03504644 2026-05-29

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Eastern Cooperative Oncology Group

Phase 1/2 Active not recruiting
40 enrolled 18 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡